Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.
Epistemonikos ID: 5d0cb408d2ca6a6457ad747bce02746896f26dcf
First added on: May 15, 2024